Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Decline in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,030,000 shares, a drop of 5.5% from the September 30th total of 1,090,000 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average daily trading volume, of 218,100 shares, the short-interest ratio is currently 4.7 days.

Context Therapeutics Price Performance

NASDAQ:CNTX traded down $0.02 during mid-day trading on Thursday, reaching $2.15. The company’s stock had a trading volume of 55,383 shares, compared to its average volume of 314,184. Context Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.75. The stock has a market cap of $161.25 million, a P/E ratio of -2.05 and a beta of 2.27. The company’s fifty day simple moving average is $2.14 and its two-hundred day simple moving average is $2.03.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Sell-side analysts expect that Context Therapeutics will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Great Point Partners LLC acquired a new position in Context Therapeutics in the 2nd quarter valued at approximately $14,876,000. Blue Owl Capital Holdings LP bought a new position in Context Therapeutics during the second quarter valued at about $10,348,000. Driehaus Capital Management LLC acquired a new stake in Context Therapeutics in the 2nd quarter worth approximately $4,527,000. Nantahala Capital Management LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter worth $3,881,000. Finally, Affinity Asset Advisors LLC raised its holdings in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.